Senhwa Biosciences, Inc. (TPEX:6492)

Market Cap	4.88B +28.3%
Revenue (ttm)	1.07M +7.0%
Net Income	-264.77M
EPS	-2.97
Shares Out	89.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	436,504
Average Volume	505,320
Open	54.40
Previous Close	54.50
Day's Range	53.80 - 55.40
52-Week Range	30.60 - 66.50
Beta	1.09
RSI	57.59
Earnings Date	May 12, 2026

About Senhwa Biosciences

Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidna...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6492

Financial Performance

In 2025, Senhwa Biosciences's revenue was 1.07 million, an increase of 7.00% compared to the previous year's 1.00 million. Losses were -264.77 million, -9.86% less than in 2024.